Therefore, the therapeutic effect of GLP-1 analogs on MASH is attributed to body weight reduction through a decrease in appetite, followed by improvement in dyslipidemia and hepatic inflammation33,34. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.